Literature DB >> 31394204

Synaptic and memory dysfunction in a β-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine.

Francisco Q Gonçalves1, João P Lopes1, Henrique B Silva1, Cristina Lemos1, António C Silva1, Nélio Gonçalves1, Ângelo R Tomé1, Samira G Ferreira1, Paula M Canas1, Daniel Rial1, Paula Agostinho2, Rodrigo A Cunha3.   

Abstract

Adenosine A2A receptors (A2AR) overfunction causes synaptic and memory dysfunction in early Alzheimer's disease (AD). In a β-amyloid (Aβ1-42)-based model of early AD, we now unraveled that this involves an increased synaptic release of ATP coupled to an increased density and activity of ecto-5'-nucleotidase (CD73)-mediated formation of adenosine selectively activating A2AR. Thus, CD73 inhibition with α,β-methylene-ADP impaired long-term potentiation (LTP) in mouse hippocampal slices, which is occluded upon previous superfusion with the A2AR antagonist SCH58261. Furthermore, α,β-methylene-ADP did not alter LTP amplitude in global A2AR knockout (KO) and in forebrain neuron-selective A2AR-KO mice, but inhibited LTP amplitude in astrocyte-selective A2AR-KO mice; this shows that CD73-derived adenosine solely acts on neuronal A2AR. In agreement with the concept that ATP is a danger signal in the brain, ATP release from nerve terminals is increased after intracerebroventricular Aβ1-42 administration, together with CD73 and A2AR upregulation in hippocampal synapses. Importantly, this increased CD73 activity is critically required for Aβ1-42 to impair synaptic plasticity and memory since Aβ1-42-induced synaptic and memory deficits were eliminated in CD73-KO mice. These observations establish a key regulatory role of CD73 activity over neuronal A2AR and imply CD73 as a novel target for modulation of early AD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31394204     DOI: 10.1016/j.nbd.2019.104570

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  25 in total

1.  Motor Deficits Coupled to Cerebellar and Striatal Alterations in Ube3am-/p+ Mice Modelling Angelman Syndrome Are Attenuated by Adenosine A2A Receptor Blockade.

Authors:  Ana Moreira-de-Sá; Francisco Q Gonçalves; João P Lopes; Henrique B Silva; Ângelo R Tomé; Rodrigo A Cunha; Paula M Canas
Journal:  Mol Neurobiol       Date:  2021-01-19       Impact factor: 5.590

2.  Neuromodulation and neuroprotective effects of chlorogenic acids in excitatory synapses of mouse hippocampal slices.

Authors:  Mara Yone D Fernandes; Fernando Dobrachinski; Henrique B Silva; João Pedro Lopes; Francisco Q Gonçalves; Felix A A Soares; Lisiane O Porciúncula; Geanne M Andrade; Rodrigo A Cunha; Angelo R Tomé
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

3.  Adenosine A2A receptors control synaptic remodeling in the adult brain.

Authors:  Ricardo J Rodrigues; Joana M Marques; Xinli Xu; Rui O Beleza; Francisco Q Gonçalves; Sergio Valbuena; Sofia Alçada-Morais; Nélio Gonçalves; Joana Magalhães; João M M Rocha; Sofia Ferreira; Ana S G Figueira; Juan Lerma; Rodrigo A Cunha
Journal:  Sci Rep       Date:  2022-08-29       Impact factor: 4.996

4.  Legumain Knockout Protects Against Aβ1-42-Induced AD-like Cognitive Deficits and Synaptic Plasticity Dysfunction Via Inhibiting Neuroinflammation Without Cleaving APP.

Authors:  Runwen Chen; Qiyue Zhang; Yuxing Yan; Yuying Zhang; Tao Zhang
Journal:  Mol Neurobiol       Date:  2020-11-21       Impact factor: 5.590

Review 5.  Metabolic Aspects of Adenosine Functions in the Brain.

Authors:  Mercedes Garcia-Gil; Marcella Camici; Simone Allegrini; Rossana Pesi; Maria Grazia Tozzi
Journal:  Front Pharmacol       Date:  2021-05-14       Impact factor: 5.810

Review 6.  Astrocytes and Adenosine A2A Receptors: Active Players in Alzheimer's Disease.

Authors:  Cátia R Lopes; Rodrigo A Cunha; Paula Agostinho
Journal:  Front Neurosci       Date:  2021-05-13       Impact factor: 4.677

Review 7.  Glial Purinergic Signaling in Neurodegeneration.

Authors:  Marie J Pietrowski; Amr Ahmed Gabr; Stanislav Kozlov; David Blum; Annett Halle; Kevin Carvalho
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

8.  Association Between Adenosine A2A Receptors and Connexin 43 Regulates Hemichannels Activity and ATP Release in Astrocytes Exposed to Amyloid-β Peptides.

Authors:  Daniela Madeira; Liliana Dias; Patrícia Santos; Rodrigo A Cunha; Paula M Canas; Paula Agostinho
Journal:  Mol Neurobiol       Date:  2021-09-02       Impact factor: 5.590

Review 9.  Adenosine A2A receptor antagonists: from caffeine to selective non-xanthines.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Pierre Matricon; Matthew T Eddy; Jens Carlsson
Journal:  Br J Pharmacol       Date:  2020-06-19       Impact factor: 9.473

Review 10.  Role of Adenosine in Epilepsy and Seizures.

Authors:  Fabio C Tescarollo; Diogo M Rombo; Lindsay K DeLiberto; Denise E Fedele; Enmar Alharfoush; Ângelo R Tomé; Rodrigo A Cunha; Ana M Sebastião; Detlev Boison
Journal:  J Caffeine Adenosine Res       Date:  2020-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.